

**Summary Report for Patient with HCC Diagnosis**  
**(Adapted from ACRIN 6690 Trial worksheet)**

<b>Total number of OPTN class 5 lesions (HCC):</b>				
<b>Lesion 1</b>				
Location		Segment		
Size (cm)	x	OPTN Class		
<b>How determined:</b>				
Increased contrast enhancement on late arterial phase (relative to hepatic parenchyma)				
Washout on portal venous/delayed phase				
Peripheral rim enhancement (capsule/pseudocapsule) on delayed phase				
Growth (maximum diameter increase in the absence of ablative therapy) by 50% or more documented on serial MRI or CT obtained < 6 month apart				
<b>Lesion 2</b>				
Location		Segment		
Size (cm)	x	OPTN Class		
<b>How determined:</b>				
Increased contrast enhancement on late arterial phase (relative to hepatic parenchyma)				
Washout on portal venous/delayed phase				
Peripheral rim enhancement (capsule/pseudocapsule) on delayed phase				
Growth (maximum diameter increase in the absence of ablative therapy) by 50% or more documented on serial MRI or CT obtained < 6 month apart				
<b>Lesion 3</b>				
Location		Segment		
Size (cm)	x	OPTN Class		
<b>How determined:</b>				
Increased contrast enhancement on late arterial phase (relative to hepatic parenchyma)				
Washout on portal venous/delayed phase				
Peripheral rim enhancement (capsule/pseudocapsule) on delayed phase				
Growth (maximum diameter increase in the absence of ablative therapy) by 50% or more documented on serial MRI or CT obtained < 6 month apart				
<b>Lesion 4</b>				
Location		Segment		
Size (cm)	x	OPTN Class		
<b>How determined:</b>				

Increased contrast enhancement on late arterial phase (relative to hepatic parenchyma)		
Washout on portal venous/delayed phase		
Peripheral rim enhancement (capsule/pseudocapsule) on delayed phase		
Growth (maximum diameter increase in the absence of ablative therapy) by 50% or more documented on serial MRI or CT obtained < 6 month apart		
Milan criteria met?	Yes	<input type="checkbox"/>
	No	<input type="checkbox"/>